Latest & greatest articles for amphetamine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on amphetamine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on amphetamine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for amphetamine

1. Amphetamine

Amphetamine Top results for amphetamine - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for amphetamine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

2. Amphetamines and methylphenidate for paediatric ADHD: meta-analysis of n-of-1 trials

Amphetamines and methylphenidate for paediatric ADHD: meta-analysis of n-of-1 trials Amphetamines and methylphenidate for paediatric ADHD Search National Elf Service Search National Elf Service » » » » Amphetamines and methylphenidate for paediatric ADHD: meta-analysis of n-of-1 trials May 24 2016 Posted by Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most common neurodevelopmental disorders, with an estimated prevalence of about 5% in school-age children (Polanczyk et al, 2007 (...) ; Polanczyk et al, 2014) and 2.5% in adults. (Simon V et al, 2009). The recommended treatment of ADHD is multimodal, including pharmacological and non-pharmacological interventions. Medications for ADHD include psychostimulant (e.g., methylphenidate and amphetamine derivatives) and non-psychostimulant drugs (e.g., atomoxetine and guanfacine). Psychostimulants are the most common drugs used for ADHD worldwide. A large body of evidence from randomised controlled trials (RCTs), summarised in several meta

2016 The Mental Elf

3. Amphetamine Full Text available with Trip Pro

Amphetamine Amphetamine - Wikipedia Amphetamine From Wikipedia, the free encyclopedia stimulant drug This article is about mixtures of and . For other uses, see . Amphetamine Clinical data Pronunciation ( ) Adderall, Adzenys XR-ODT , Dyanavel XR, Evekeo, Synonyms α-methylphenethylamine / (Risk not ruled out) : none : moderate Moderate Medical: , Recreational: , , , , , ( ) Legal status (Controlled) (Psychoactive drugs) (Special prescription form required) data Oral: 75–100% 15–40 (...) % , , , , , , , , -dependent: 7–34 hours Primarily ; -dependent range: 1–75% Identifiers ( RS )-1-phenylpropan-2-amine Y Y Y Y Y Y Chemical and physical data C 9 H 13 N 135.20622 g/mol g·mol −1 3D model ( ) .936 g/cm 3 at 25 °C 11.3 °C (52.3 °F) (predicted) 203 °C (397 °F) at 760 NC(CC1=CC=CC=C1)C InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3 Y Key:KWTSXDURSIMDCE-UHFFFAOYSA-N Y Amphetamine (contracted from - ) is a (CNS) that is used in the treatment of (ADHD), , and . Amphetamine was discovered in 1887

2012 Wikipedia

4. Effects of lisdexamfetamine on plasma steroid concentrations compared with d-amphetamine in healthy subjects: A randomized, double-blind, placebo-controlled study. Full Text available with Trip Pro

Effects of lisdexamfetamine on plasma steroid concentrations compared with d-amphetamine in healthy subjects: A randomized, double-blind, placebo-controlled study. The novel d-amphetamine prodrug lisdexamfetamine is applied to treat attention-deficit/hyperactivity disorder (ADHD). d-Amphetamine releases dopamine and norepinephrine and stimulates the hypothalamic-pituitary-adrenal (HPA) axis, which may contribute to its reinforcing effects and risk of abuse. However, no data is currently (...) available on the effects of lisdexamfetamine on circulating steroids. This randomized, double-blind, placebo-controlled, cross-over study evaluated the effects of equimolar doses of d-amphetamine (40 mg) and lisdexamfetamine (100 mg) and placebo on circulating steroids in 24 healthy subjects. Plasma steroid and d-amphetamine levels were determined up to 24 h. Delayed increase and peak levels of plasma d-amphetamine concentrations were observed following lisdexamfetamine treatment compared with d

2019 The Journal of steroid biochemistry and molecular biology Controlled trial quality: uncertain

5. Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. Full Text available with Trip Pro

Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. The prescription use of the stimulants methylphenidate and amphetamine for the treatment of attention deficit-hyperactivity disorder (ADHD) has been increasing. In 2007, the Food and Drug Administration mandated changes to drug labels for stimulants on the basis of findings of new-onset psychosis. Whether the risk of psychosis in adolescents and young adults with ADHD differs among various stimulants has not been extensively (...) studied.We used data from two commercial insurance claims databases to assess patients 13 to 25 years of age who had received a diagnosis of ADHD and who started taking methylphenidate or amphetamine between January 1, 2004, and September 30, 2015. The outcome was a new diagnosis of psychosis for which an antipsychotic medication was prescribed during the first 60 days after the date of the onset of psychosis. To estimate hazard ratios for psychosis, we used propensity scores to match patients who

2019 NEJM

6. Amphetamine

II. Class Schedule II III. Preparations: ( ) ( ) Propylhexedrine IV. Street Names Bennies Speed Pep Pills Hearts Wake-ups Uppers V. Pharmacokinetics Amphetamine (5-250 mg): 4-12 hour duration VI. Routes Swallowed Intravenous Smoked (ice or crystal ) VII. Medical uses Relieves mild depression Control appetite and VIII. Effects of heavy or prolonged use Loss of appetite s s Toxic IX. Signs: Toxicity See Similar to , longer duration >2 hours Adverse reaction also similar to X. Toxicity Management (...) Amphetamine Amphetamine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Amphetamine Amphetamine Aka: Amphetamine From Related Chapters

2018 FP Notebook

7. Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate

Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03659929 Recruitment Status : Active, not recruiting First Posted : September 6, 2018 Last Update Posted : February 20, 2019 Sponsor: Arbor Pharmaceuticals

2018 Clinical Trials

8. Adjunctive Mixed Salts Amphetamine (MSA) for Depressed Adults With Incomplete Response to Current Antidepressant Therapy (ADT)

Adjunctive Mixed Salts Amphetamine (MSA) for Depressed Adults With Incomplete Response to Current Antidepressant Therapy (ADT) Adjunctive Mixed Salts Amphetamine (MSA) for Depressed Adults With Incomplete Response to Current Antidepressant Therapy (ADT) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Adjunctive Mixed Salts Amphetamine (MSA) for Depressed Adults With Incomplete Response to Current Antidepressant Therapy (ADT) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02058693 Recruitment Status

2014 Clinical Trials

9. Insights into the Modulation of Dopamine Transporter Function by Amphetamine, Orphenadrine, and Cocaine Binding Full Text available with Trip Pro

Insights into the Modulation of Dopamine Transporter Function by Amphetamine, Orphenadrine, and Cocaine Binding Human dopamine (DA) transporter (hDAT) regulates dopaminergic signaling in the central nervous system by maintaining the synaptic concentration of DA at physiological levels, upon reuptake of DA into presynaptic terminals. DA translocation involves the co-transport of two sodium ions and the channeling of a chloride ion, and it is achieved via alternating access between outward-facing (...) (OF) and inward-facing states of DAT. hDAT is a target for addictive drugs, such as cocaine, amphetamine (AMPH), and therapeutic antidepressants. Our recent quantitative systems pharmacology study suggested that orphenadrine (ORPH), an anticholinergic agent and anti-Parkinson drug, might be repurposable as a DAT drug. Previous studies have shown that DAT-substrates like AMPH or -blockers like cocaine modulate the function of DAT in different ways. However, the molecular mechanisms of modulation remained

2015 Frontiers in neurology

10. Effects of d-amphetamine upon psychosocial stress responses. (Abstract)

Effects of d-amphetamine upon psychosocial stress responses. Psychostimulant drugs alter the salience of stimuli in both laboratory animals and humans. In animals, stimulants increase rates of responding to conditioned incentive stimuli, and in humans, amphetamine increases positive ratings of emotional images. However, the effects of stimulants on real-life emotional events have not been studied in humans. In this study, we examined the effect of d-amphetamine on responses to acute (...) psychosocial stress using a public speaking task. Healthy volunteers (N=56) participated in two experimental sessions, one with a psychosocial stressor (the Trier Social Stress Test) and one with a non-stressful control task. They were randomly assigned to receive d-amphetamine (5 mg n=18, 10 mg n=20) or placebo (n=18) on both sessions under double blind conditions. Salivary cortisol, subjective mood, and vital signs were measured at regular intervals during the session. Subjects also provided cognitive

2016 Journal of psychopharmacology (Oxford, England)

11. Impaired skeletal health and neuromuscular function among amphetamine users in clinical treatment. Full Text available with Trip Pro

Impaired skeletal health and neuromuscular function among amphetamine users in clinical treatment. This study examined musculoskeletal health in amphetamine users, compared with healthy age-matched controls. We show that amphetamine users have reduced bone mass at several skeletal sites and attenuated maximal muscle strength and force development capacity in the lower extremities.Amphetamine use may cause poor bone quality and elevated risk of osteoporosis. The purpose of this study (...) was to investigate whether amphetamine users exhibit reduced regional and whole body bone mineral density (BMD), altered bone metabolism, and how muscle function may relate to the patient groups' skeletal health.We assessed hip, lumbar spine and whole body BMD, and trabecular bone score (TBS) by dual x-ray absorptiometry (DXA), and bone metabolism markers in serum and maximal strength and force development capacity in 36 amphetamine users (25 men, 30 ± 7 years; 11 women 35 ± 10 years) and in 37 healthy controls

2015 Osteoporosis International

12. Death in amphetamine users: causes and rates. Full Text available with Trip Pro

Death in amphetamine users: causes and rates. The world medical literature contains 43 reports of deaths associated with amphetamines in a 35-year period. These included seven cerebrovascular accidents, six sudden cardiac deaths, three cases of hyperpyrexia, eight poisonings of uncertain mechanism and seven cases of medical complications of intravenous injection; the remainder were of uncertain cause. In contrast, in Ontario alone, in 1972 and 1973 there were 26 deaths in amphetamine users (...) , of which 16 were due to accident suicide or homicide. Of the remaining cases, two were cardiac, two hepatic and the rest were mixed drug overdose. Pulmonary granulomata, subacute hepatitis and other lesions resulting from intravenous drug use were common findings at autopsy. On the basis of the estimated number of regular users of intravenous amphetamine in Ontario, the mortality rate in such users is at least four times as high as in the general population of the same age, and is comparable

1975 Canadian Medical Association Journal

13. Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium. Full Text available with Trip Pro

Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium. Given the rapidly increasing use of stimulant medications during pregnancy and among women of reproductive age who may become pregnant inadvertently, there is a need to better understand their safety.To examine the risk of congenital malformations associated with intrauterine exposure to stimulants.Cohort study (...) psychiatric disorders and other potential confounders. Relative risk estimates for the US and Nordic data were pooled using a fixed-effects meta-analytic approach. The study was conducted from July 1, 2015, to March 31, 2017.Methylphenidate and amphetamines dispensed during the first trimester.Major congenital malformations and subgroup of cardiac malformations.In the US data, of the 1 813 894 pregnancies evaluated, 35.0 per 1000 infants not exposed to stimulants were diagnosed as having congenital

2017 JAMA psychiatry (Chicago, Ill.)

14. The role of neurotrophic factors in manic-, anxious- and depressive-like behaviors induced by amphetamine sensitization: Implications to the animal model of bipolar disorder. (Abstract)

The role of neurotrophic factors in manic-, anxious- and depressive-like behaviors induced by amphetamine sensitization: Implications to the animal model of bipolar disorder. Bipolar disorder (BD) and substance use disorders share common symptoms, such as behavioral sensitization. Amphetamine-induced behavioral sensitization can serve as an animal model of BD. Neurotrophic factors have an important role in BD pathophysiology. This study evaluated the effects of amphetamine sensitization (...) , while NT-3 and NT-4 levels were increased in brains after d-AMPH sensitization.Although d-AMPH induces manic-like behavior, the mechanisms underlying these effects can also be related to phenotypes of drug abuse.Together, vulnerability to mania-like behavior following d-AMPH challenge and extensive neurotrophic alterations, suggest amphetamine-induced behavioral sensitization is a good model of BD pathophysiology.Copyright © 2018. Published by Elsevier B.V.

2019 Journal of Affective Disorders

15. A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users

A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information (...) . Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does

2017 Clinical Trials

16. Individual Differences in Frontal Cortical Thickness Correlate with the d-Amphetamine-Induced Striatal Dopamine Response in Humans. Full Text available with Trip Pro

Individual Differences in Frontal Cortical Thickness Correlate with the d-Amphetamine-Induced Striatal Dopamine Response in Humans. The meso-striatal dopamine system influences responses to rewards and the motivation to seek them out. Marked individual differences in these responses are seen in laboratory animals, related in part to input from the prefrontal cortex. Here we measured the relation between cortical morphology and drug-induced striatal dopamine release in healthy young people (...) . Participants were 24 (17 male, 7 female; age 23.0 ± 6.2 years) stimulant drug-naive subjects who underwent PET [(11)C]raclopride scans with 0.3 mg/kg d-amphetamine orally and placebo, and an anatomical MRI scan for measuring cortical thickness. As expected, d-amphetamine produced significant reductions in [(11)C]raclopride binding potential in the striatum as a percentage of the value in the placebo condition. There was substantial individual variability in this response, which was correlated with cortical

2013 The Journal of neuroscience : the official journal of the Society for Neuroscience

17. Personality and the acute subjective effects of d-amphetamine in humans. Full Text available with Trip Pro

Personality and the acute subjective effects of d-amphetamine in humans. There is evidence that subjective responses to psychoactive drugs are related to personality traits. Here, we extend previous findings by examining personality measures in relation to acute responses to d-amphetamine (AMPH) in a large sample of healthy volunteers. Healthy adults (n=286) completed the Multidimensional Personality Questionnaire Brief Form (MPQ-BF) and participated in four sessions during which they received (...) fearlessness was significantly associated with greater amphetamine-related Arousal, and high trait reward sensitivity was significantly associated with greater Euphoria. In addition, high trait impulsivity was significantly associated with greater Arousal and Euphoria. These results provide further evidence that individual differences in the subjective effects of AMPH are partially explained by differences in personality, and are consistent with the idea that both personality and responses to stimulants

2013 Journal of psychopharmacology (Oxford, England) Controlled trial quality: uncertain

18. Amphetamine-type stimulant use and HIV/STI risk behaviour among young female sex workers in Phnom Penh, Cambodia Full Text available with Trip Pro

Amphetamine-type stimulant use and HIV/STI risk behaviour among young female sex workers in Phnom Penh, Cambodia Use of amphetamine-type substances (ATS) has been linked to increased risk of HIV and other sexually transmitted infections (STI) worldwide. In Cambodia, recent ATS use is independently associated with incident STI infection among young female sex workers (FSWs).We conducted 33 in-depth interviews with women (15-29 years old) engaged in sex work to explore ATS use and vulnerability (...) to HIV/STI.Participants reported that ATS, primarily methamphetamine in pill and crystalline forms (yama), were cheap, widely available and commonly used. Yama was described as a "power drug" (thnam kamlang) which enabled women to work long hours and serve more customers. Use of ATS by clients was also common, with some providing drugs for women and/or encouraging their use, often resulting in prolonged sexual activity. Requests for unprotected sex were also more common among alternatives intoxicated

2011 The International journal on drug policy

19. Comparison of the behavioral and cardiovascular effects of intranasal and oral d-amphetamine in healthy human subjects. Full Text available with Trip Pro

Comparison of the behavioral and cardiovascular effects of intranasal and oral d-amphetamine in healthy human subjects. Recent reports indicate an increase in intranasal use of prescription oral stimulant medication. However, there do not appear to be any published clinical studies that have characterized the behavioral and cardiovascular effects of intranasally administered d-amphetamine, which is commonly prescribed for Attention Deficit Hyperactivity Disorder. In this study, a range of d (...) -amphetamine doses (0, 16, 24, and 32 mg/70 kg) were administered as an intranasal solution delivered using a mucosal atomization device. Equal oral doses were included for comparison. Assessments were conducted before and at regular intervals for 3 hours following drug administration and included self-reported drug-effect questionnaires, cardiovascular indices, a performance task, and 2 measures of impulsivity. d-Amphetamine produced prototypical stimulant effects (eg, increased subject ratings

2011 Journal of clinical pharmacology Controlled trial quality: uncertain

20. Effects of amphetamine on reactivity to emotional stimuli. Full Text available with Trip Pro

Effects of amphetamine on reactivity to emotional stimuli. Most studies of the reinforcing effects of stimulants have focused on the drugs' capacity to induce positive mood (i.e., euphoria). However, recent findings suggest drugs may also alter emotional reactivity to external stimuli, and that this may occur independently of direct effects on mood.We aimed to examine effects of D: -amphetamine, a prototypic stimulant, on self-reported and psychophysiological reactivity to emotional stimuli (...) as well as overall subjective mood. We predicted that amphetamine would enhance reactivity to pleasant stimuli, particularly, stimuli with social content and that these effects would be independent of the drug's direct effects on mood.Over three sessions, 36 healthy normal adults received placebo, D: -amphetamine 10 and 20 mg under counterbalanced double-blind conditions. At each session, emotional reactivity to standardized positive, neutral, and negative pictures with and without social content

2012 Psychopharmacology Controlled trial quality: uncertain